TScan Therapeutics, Inc. (TCRX) - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on March 9, 2022, by TScan Therapeutics, Inc., a Delaware corporation. The filing serves to announce the company's financial results for the quarter and full year ended December 31, 2021. The detailed results are contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the accompanying press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing text does not provide specific data regarding material changes versus prior periods. It only confirms the announcement of results for the period ended December 31, 2021.
Guidance, Outlook, and Risks
The filing text does not include specific guidance, outlook, management commentary, or risk factors. It notes that the information in Item 2.02 and Exhibit 99.1 is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 9, 2022) for actual revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate based on the full-year 2021 results.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the press release.
- Confirm the status of the company's emerging growth company election and any related accounting transitions.